|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||99.03 - 103.16|
|52 Week Range||49.03 - 163.08|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||150.19|
|Earnings Date||Nov 01, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||105.29|
Staar Surgical (STAA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
STAAR Surgical (NASDAQ: STAA) stock was up by 16% as of 3:36 p.m. ET on Thursday after it smashed the market's expectations for its second-quarter earnings, reporting net sales of $81.1 million and $0.26 in net income per diluted share. The strong sales in China and India indicate that STAAR's ongoing push into major international vision correction markets is going swimmingly. Right now, its market share in China is estimated to be above 20%, which bodes well for its future performance there.